We estimated the effects of a rat fetal neurogenic cell supernatant (RFNCS) on proliferative activity of cultured cells of rat brain glioma (C6 cell line). The RFNCS was obtained from a cell suspension of the brains from rat fetuses (gestation day 14, E14). We added 0.10 mg/ml of RFNCS to the culture medium of experimental cultures and incubated the latter for 48 h. Immunocytochemical staining with respect to the Ki-67 proliferation marker was performed using rabbit monoclonal antibodies against this protein. In glioma C6 cell cultures, we observed degenerating and necrobiotically modified tumor cells with rounded cell bodies and reduction of the processes. Under the action of RFNCS, the mean density of the cells in 10 test fields of vision in experimental cultures (0.04 mm2) became significantly smaller than that in the control (332.0 ± 36.0 vs. 569.5 ± 70.5; P = 0.00026); the mean value of the nuclear/cytoplasmic ratio in malignant cells mildly (insignificantly) decreased (0.28 ± 0.01 vs. 0.32 ± 0.02; P = 0.64) and the share of cells with multiple nucleoli was more than two times smaller (3.53 ± 0.33% and 7.97 ± 0.25%, respectively; P = 0.053). The mitotic index of cultured malignant cells subjected to the action of RFNCS became four times lower (1.10 ± 0.04% vs. 4.90 ± 0.09%; P = 0.009), while the share of malignant cells immunopositive with respect to Ki-67 decreased (10.47 ± 0.91% vs. 27.86 ± ± 2.91%; P = 0.0015). The observed antiproliferative effect of RFNCS confirms the possibility and expedience of the development of complex pathogenetic therapy for malignant tumors of the brain using preparations obtained from fetal neurogenic cells.
Similar content being viewed by others
References
“Cancer in Ukraine, 2013-2014. Morbidity, mortality, and indices of activity of oncologic service,” Byul. Nats. Cancer Register, No. 16, 56-57 (2015).
L. Ampie, E. C. Woolf, and C. Dardis, “Immunotherapeutic advancements for glioblastoma,” Front. Oncol., 5, 1-8 (2015).
Ch. I. Ene and E. C. Holland, “Personalized medicine for gliomas,” Surg. Neurol. Int., 6, No. 1, S89-S95 (2015).
Yu. A. Zozulya, I. G. Vasil’yeva, A. Ya. Glavatskii, et al., “Photodynamic therapy for brain gliomas,” in: Gliomas of the Brain [in Russian], Yu. A. Zozulya (ed.). UIPK, EksOb, Kyiv (2007), pp. 495-501.
I. S. Bryukhovetskii, A. S. Bryukhovetskii, P. V. Mishchenko, et al., “Stem cells in therapy against malignant tumor of the brain: reality and prospects,” Klin. Praktika. No. 4, 45-57 (2013).
P. Achanta, N. I. Sedora Roman, and A. Quiñones-Hinojosa, “Gliomagenesis and the use of neural stem cells in brain tumor treatment,” Anticancer Agents Med. Chem., 10, No. 2, 121-130 (2010).
A. U. Ahmed, I. V. Ulasov, R. W. Mercer, and M. S. Lesniak, “Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors,” Methods Mol. Biol., 797, 97-109 (2012).
M. S. Bovenberg, M. H. Degeling, and B. A. Tannous, “Advances in stem cell therapy against gliomas,” Trends Mol. Med., 19, No. 5, 281-291 (2013).
S. Ito, A. Natsume, S. Shimato, et al., “Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma,” Cancer Gene Ther., 17, No. 5, 299-306 (2010).
S. U. Kim, “Neural stem cell-based gene therapy for brain tumors,” Stem Cell Rev., 7, No. 1, 130-140 (2011).
J. Y. Jeon, J. H. An, S. U. Kim, et al., “Migration of human neural stem cells toward an intracranial glioma,” Exp. Mol. Med., 40, No. 1, 84-91 (2008).
K. Staflin, M. Lindvall, T. Zuchner, and C. Lundberg, “Instructive cross-talk between neural progenitor cells and gliomas,” J. Neurosci. Res., 85, No. 10, 2147-2159 (2007).
K. Staflin, G. Honeth, S. Kalliomaki, et al., “Neural progenitor cell lines inhibit rat tumor growth in vivo,” Cancer Res., 64, No. 15, 5347-5354 (2004).
J. H. Walzlein, M. Synowitz, B. Engels, et al., “The antitumorigenic response of neural precursors depends on subventricular proliferation and age,” Stem Cells, 26, No. 11, 2945-2954 (2008).
N. I. Lisyanyi, G. M. Oleinik, O. V. Markova, et al., “Effect of cerebral cells on growth of tumors under renal capsule in vivo,” in: Immune System of the Brain [in Russian], N. I. Lisyanyi (ed.), VIPOL, Kyiv (1999), pp. 116-135.
V. M. Semenova, V. I. Tsymbalyuk, L. P. Staino, et al., “Study of antitumor properties of different populations of brain cells in culture of neural tissue,” in: Immune System of the Brain [in Russian], N. I. Lisyanyi (ed.), VIPOL, Kyiv (1999), pp. 136-146.
N. I. Lisyanyi, L. D. Liubich, and O. G. Khokhlov, “Study of antitumor action of progenitor neural cells (NC) in rats with experimental glioma of the brain,” Immunol, Allergol., No. 3, 61-66 (2008).
V. M. Semenova, Experimental Morphological Estimate of the Efficacy of Antiblastic Therapy for Gliomas of the Brain [in Russian], Doctoral Thesis, Med. Sci., Kyiv (1992).
H. J. Klassen, K. L. Imfeld, I. I. Kirov, et al., “Expression of cytokines by multipotent neural progenitor cells,” Cytokine, 22, Nos. 3/4, 101-106 (2003).
H. C. Chen, H. I. Ma, H. K. Sytwu, et al., “Neural stem cells secrete factors that promote auditory cell proliferation via a leukemia inhibitory factor signaling pathway,” J. Neurosci. Res., 88, No. 15, 3308-3318 (2010).
J. Liu, C. Götherström, M. Forsberg, et al., “Human neural stem/progenitor cells derived from embryonic stem cells and fetal nervous system present differences in immunogenicity and immunomodulatory potentials in vitro,” Stem Cell Res., 10, No. 3, 325-337 (2013).
L. D. Liubich, V. M. Semenova, and L. P. Stayno, “Influence of rat progenitor neurogenic cells supernatant on glioma 101.8 cells in vitro,” Biopolymers Cell, 31, No. 3, 200-208 (2015).
B. Kaminska, M. Kocyk, and M. Kijewska, “TGF beta signaling and its role in glioma pathogenesis,” Adv. Exp. Med. Biol., 986, 171-187 (2013).
J. Zhang, W. Yang, D. Zhao, et al., “Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density,” Oncol. Lett., 7, No. 1, 95-100 (2014).
A. M. Dubrovska and S. S. Souchelnytskyi, “Low-density microarray analysis of TGFb1-dependent cell cycle regulation in human breast adenocarcinoma MCG7 cell line,” Biopolymers Cell, 30, No. 2, 107-117 (2014).
D. K. Binder and H. E. Scharfman, “Brain-derived neurotrophic factor,” Growth Factors, 22, No. 3, 123-131 (2004).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Liubich, L.D., Semenova, V.M., Malysheva, T.A. et al. Effects of a Supernatant of Fetal Neurogenic Cells on Proliferative Activity in Glioma C6 Cell Culture. Neurophysiology 48, 238–245 (2016). https://doi.org/10.1007/s11062-016-9594-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11062-016-9594-6